Mersana Therapeutics to Present at Wedbush PacGrow Healthcare Conference
August 09 2017 - 10:28AM
Business Wire
Mersana Therapeutics, Inc. (NASDAQ:MRSN), today announced that
Anna Protopapas, President and Chief Executive Officer, will
present a company overview at the Wedbush PacGrow Healthcare
Conference in New York City on Wednesday, August 16, 2017, from
10:20-10:50am EDT.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical
company using its differentiated and proprietary ADC platforms to
develop highly targeted drugs with increased tolerability and
expanded opportunities to deliver meaningful clinical benefit to
patients. Mersana’s lead product candidate, XMT-1522, is in Phase I
clinical trials in patients with advanced tumors expressing HER2,
including breast cancer, non-small-cell-lung-cancer (NSCLC) and
gastric cancer patients. The Company expects that its second
product candidate, XMT-1536, will enter clinical trials in early
2018. In addition, multiple partners are using Mersana’s leading
platform to advance their ADC pipelines.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170809005756/en/
Mersana Therapeutics, Inc.Media ContactPaul Kidwell,
617-680-1088paulkidwell@comcast.netorInvestors ContactStern
Investor Relations, Inc.Christina Tartaglia,
212-362-1200Christina@sternir.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024